SK

Suresh Kumar Nandiraju

Active Director Director DIN 02548952
DIN 02548952 First appointment Aug 1999 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 6 active board seats
Past companies 6 historical roles
Total affiliations 12 Since Aug 1999
Shareholding value •••• Premium profile

About Suresh Kumar Nandiraju

Data last updated:

Suresh Kumar Nandiraju is a Director at Clinsync Clinical Research Private Limited (since 2024), Director at Pharmarics Private Limited (since 2021) and Director at Vinda Healthcare Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Pharma, Chemicals and Construction. The 3 current companies with reported revenue have a combined latest revenue of ₹15.83 Cr; the largest is Clinsync Clinical Research Private Limited at ₹15.75 Cr (FY 2025). Earlier, Suresh Kumar Nandiraju was a Director at Omnicare Drugs India Private Limited (2017–2020) and Additional Director at Benta Pharma Private Limited (2023–2024) and 4 more.

DIN 02548952
Primary Designation Director
Industry Pharma
First Appointment 10 Aug 1999
Oldest Company Age 27 yrs
Largest company Clinsync Clinical Research Private Limited · ₹15.75 Cr (FY 2025)
Combined revenue ₹15.83 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Aug 20242011₹15.75 Cr (FY 2025)Active
Pharmarics Private Limited U24299TG2021PTC157707
Director07 Dec 20212021₹5.2 Lakh (FY 2025)Active
Vinda Healthcare Private Limited U74999TG2017PTC114312
Director13 Jun 20252017₹3 Lakh (FY 2024)Active
Vidur Human Care Private Limited U24304TG2018PTC123108
Director19 Jul 20252018Active
Osr Projects Llp AAM-7496
Designated Partner04 Jun 20182018Active
Ala Realtors Private Limited U70100TG1999PTC032270
Director10 Aug 19991999Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Omnicare Drugs India Private Limited U74999TG2017PTC116303
Director03 Apr 20172017₹82.01 Cr (FY 2019)Active
Benta Pharma Private Limited U21002TS2023PTC171849
Additional Director31 Jul 20232023Active
Neoaska Pharma Private Limited U74999TG2017PTC119969
Director10 Oct 20172017₹3.2 Lakh (FY 2025)Active
Therapiva Private Limited U73100TG2017PTC120931
Director01 Dec 20172017₹149 Cr (FY 2021)Active
Pavo Capital India Private Limited U65990TG2022PTC158852
Director18 Jan 20222022Strike Off
Yogitha Enterprises Private Limited U74900TG2014PTC093876
Director08 Jan 20182014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Osr Projects Llp
Pharmarics Private Limited
Pavo Capital India Private Limited
Ala Realtors Private Limited
Premium access

Shareholding and investment profile for Suresh Kumar Nandiraju

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suresh Kumar Nandiraju

Suresh Kumar Nandiraju currently holds 6 directorships: Clinsync Clinical Research Private Limited (Director, since 26 Aug 2024, revenue ₹15.75 Cr (FY 2025)); Pharmarics Private Limited (Director, since 07 Dec 2021, revenue ₹5.2 Lakh (FY 2025)); Vinda Healthcare Private Limited (Director, since 13 Jun 2025, revenue ₹3 Lakh (FY 2024)); Vidur Human Care Private Limited (Director, since 19 Jul 2025); Osr Projects Llp (Designated Partner, since 04 Jun 2018); and 1 more.

Suresh Kumar Nandiraju was first appointed on 10 Aug 1999 as Director at Ala Realtors Private Limited. The most recent appointment on record is 19 Jul 2025 at Vidur Human Care Private Limited.

The 3 current companies of Suresh Kumar Nandiraju that report revenue have a combined latest revenue of ₹15.83 Cr: Clinsync Clinical Research Private Limited ₹15.75 Cr (FY 2025); Pharmarics Private Limited ₹5.2 Lakh (FY 2025); Vinda Healthcare Private Limited ₹3 Lakh (FY 2024).

Suresh Kumar Nandiraju held 6 earlier board appointments: Omnicare Drugs India Private Limited (Director, 03 Apr 2017 to 08 Aug 2020); Benta Pharma Private Limited (Additional Director, 31 Jul 2023 to 30 Sep 2024); Neoaska Pharma Private Limited (Director, 10 Oct 2017 to 13 Jul 2023); Therapiva Private Limited (Director, 01 Dec 2017 to 08 Aug 2020); Pavo Capital India Private Limited (Director, from 18 Jan 2022); and 1 more.

The current boards of Suresh Kumar Nandiraju's companies include Attili Venkata Satya Suresh (Clinsync Clinical Research Private Limited), Koteswara Prasad Sripathipanditaradhyula (Clinsync Clinical Research Private Limited), Sandhya Nandiraju (Clinsync Clinical Research Private Limited), Rajendra Hemchand Bhandari (Pharmarics Private Limited), Khalil Ahmed Shaikh (Vidur Human Care Private Limited), Ramakrishnan Sishtla (Vidur Human Care Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available